Biophan CEO Michael Weiner Discusses Company's Breakthrough Biomedical Technologies in Interview with CEOcast.com; CEO Provides Overview of Propriety Solutions and Commercialization Strategy
Mr. Weiner provided explanations of Biophan's proprietary technology development initiatives to provide significant solutions for the biomedical industry. He also provided an overview of the Company's business strategy to license its technology to the biomedical industry's major manufacturers of medical devices, to enable these manufacturers to create safer, competitively advantageous products in important markets. Biophan has signed a term sheet with leading medical device maker Boston Scientific and is in discussions with other manufacturers worldwide.
Among the Biophan solutions Mr. Weiner discussed are the Company's proprietary nanotechnology-based and other next-generation approaches to make vascular stents and pacemakers both safe and imageable by Magnetic Resonance Imaging (MRI) systems. MRI systems are uniquely powerful diagnostic imaging devices, but are contraindicated for use with certain common implanted medical devices, such as cardiovascular stents or pacemakers.
The streaming audio interview is available free of charge to interested investors. To access the interview, visit http://www.ceocast.com.
CEOcast is the premier source of original and syndicated streaming broadcast interviews of Chief Executive Officers at public and private news-making companies. Organized by industry, its analysts average over 15 years experience covering and evaluating Wall Street's leading companies. CEOcast's programming is distributed to on-line investors at over numerous financial web sites as well as to many portfolio managers, buy-side analysts and traders at North American institutions. Content is also disseminated to investment research professionals representing a substantial number of institutions.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 114 U.S. patents, licenses, or applications. This total includes 36 issued U.S. patents, 6 recently-allowed applications that will issue as patents in the near future, and 72 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.